Fortitude Family Office’s Century Therapeutics IPSC Stock Holding History

Fortitude Family Office’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$503	Hold	294	–	–	﹤0.01%	2407
2026 Q2	$720	Hold	294	–	–	﹤0.01%	1872
2026 Q1	$664	Buy	+294	New	+$618	﹤0.01%	1625

Other funds holding IPSC

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

FIA

FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Fortitude Family Office's IPSC Position: Q3 2026 in Review

Fortitude Family Office held its Century Therapeutics (IPSC) position steady in Q3 2026 at 294 shares worth $503. The position accounts for ﹤0.01% of the portfolio, ranked #2407.

Fortitude Family Office first reported a position in IPSC in Q1 2026 and has held it in 3 quarters since. The position peaked at $720 in Q2 2026. 5 funds tracked by Wall St. Rank hold IPSC as of Q3 2026.

Fortitude Family Office held 294 shares of Century Therapeutics worth $503 as of Q3 2026.
Fortitude Family Office left its Century Therapeutics share count unchanged in Q3 2026.
Century Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #2407 holding.
Fortitude Family Office first reported a position in Century Therapeutics in Q1 2026 and has held it in 3 quarters since.
Fortitude Family Office's Century Therapeutics position peaked at $720 in Q2 2026.
5 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.